138 related articles for article (PubMed ID: 30279194)
21. Circulating cell-free DNA in plasma of colorectal cancer patients - A potential biomarker for tumor burden.
Bhangu JS; Taghizadeh H; Braunschmid T; Bachleitner-Hofmann T; Mannhalter C
Surg Oncol; 2017 Dec; 26(4):395-401. PubMed ID: 29113658
[TBL] [Abstract][Full Text] [Related]
22. Clinical relevance of cell-free DNA in gastrointestinal tract malignancy.
Lan YT; Chen MH; Fang WL; Hsieh CC; Lin CH; Jhang FY; Yang SH; Lin JK; Chen WS; Jiang JK; Lin PC; Chang SC
Oncotarget; 2017 Jan; 8(2):3009-3017. PubMed ID: 27936467
[TBL] [Abstract][Full Text] [Related]
23. Clonal evolution in the transition from cutaneous disease to acute leukemia suggested by liquid biopsy in blastic plasmacytoid dendritic cell neoplasm.
Ladikou E; Ottolini B; Nawaz N; Allchin RL; Payne D; Ali H; Marafioti T; Shaw J; Ahearne MJ; Wagner SD
Haematologica; 2018 May; 103(5):e196-e199. PubMed ID: 29419438
[No Abstract] [Full Text] [Related]
24. Cancer Special Issue: Early detection and minimal residual disease.
Odeny B
PLoS Med; 2021 Oct; 18(10):e1003794. PubMed ID: 34637442
[TBL] [Abstract][Full Text] [Related]
25. Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA.
Chae YK; Davis AA; Carneiro BA; Chandra S; Mohindra N; Kalyan A; Kaplan J; Matsangou M; Pai S; Costa R; Jovanovic B; Cristofanilli M; Platanias LC; Giles FJ
Oncotarget; 2016 Oct; 7(40):65364-65373. PubMed ID: 27588476
[TBL] [Abstract][Full Text] [Related]
26. Liquid Biopsy for the Management of Patients with Colorectal Cancer.
Yamada T; Matsuda A; Koizumi M; Shinji S; Takahashi G; Iwai T; Takeda K; Ueda K; Yokoyama Y; Hara K; Hotta M; Matsumoto S; Yoshida H
Digestion; 2019; 99(1):39-45. PubMed ID: 30554222
[TBL] [Abstract][Full Text] [Related]
27. IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing.
Deans ZC; Butler R; Cheetham M; Dequeker EMC; Fairley JA; Fenizia F; Hall JA; Keppens C; Normanno N; Schuuring E; Patton SJ
Virchows Arch; 2019 Jun; 474(6):681-689. PubMed ID: 31028539
[TBL] [Abstract][Full Text] [Related]
28. The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment.
Demuth C; Madsen AT; Weber B; Wu L; Meldgaard P; Sorensen BS
BMC Cancer; 2018 Feb; 18(1):191. PubMed ID: 29448920
[TBL] [Abstract][Full Text] [Related]
29. Highly sensitive and specific real-time PCR by employing serial invasive reaction as a sequence identifier for quantifying EGFR mutation abundance in cfDNA.
Xiang Z; Wan R; Zou B; Qi X; Huang Q; Kumar S; Pitman JL; Zhou G; Song Q
Anal Bioanal Chem; 2018 Oct; 410(26):6751-6759. PubMed ID: 30128808
[TBL] [Abstract][Full Text] [Related]
30. Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
Spindler KG; Boysen AK; Pallisgård N; Johansen JS; Tabernero J; Sørensen MM; Jensen BV; Hansen TF; Sefrioui D; Andersen RF; Brandslund I; Jakobsen A
Oncologist; 2017 Sep; 22(9):1049-1055. PubMed ID: 28778958
[TBL] [Abstract][Full Text] [Related]
31. Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer.
Bennett CW; Berchem G; Kim YJ; El-Khoury V
Oncotarget; 2016 Oct; 7(43):71013-71035. PubMed ID: 27589834
[TBL] [Abstract][Full Text] [Related]
32. Liquid biopsy of fine-needle aspiration supernatant for lung cancer genotyping.
Guibert N; Tsukada H; Hwang DH; Chambers E; Cibas ES; Bale T; Supplee J; Ulrich B; Sholl LM; Paweletz CP; Oxnard GR
Lung Cancer; 2018 Aug; 122():72-75. PubMed ID: 30032849
[TBL] [Abstract][Full Text] [Related]
33. Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer.
Imamura F; Uchida J; Kukita Y; Kumagai T; Nishino K; Inoue T; Kimura M; Oba S; Kato K
Lung Cancer; 2016 Apr; 94():68-73. PubMed ID: 26973209
[TBL] [Abstract][Full Text] [Related]
34. Simple and cost-effective laboratory methods to evaluate and validate cell-free DNA isolation.
Mojtabanezhad Shariatpanahi A; Rokni P; Shahabi E; Varshoee Tabrizi F; Kerachian MA
BMC Res Notes; 2018 Oct; 11(1):757. PubMed ID: 30352614
[TBL] [Abstract][Full Text] [Related]
35. Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.
Coco S; Alama A; Vanni I; Fontana V; Genova C; Dal Bello MG; Truini A; Rijavec E; Biello F; Sini C; Burrafato G; Maggioni C; Barletta G; Grossi F
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28492516
[TBL] [Abstract][Full Text] [Related]
36. Trapping Cancers as They Adapt to Survive.
Haq R
Cancer Discov; 2017 Nov; 7(11):1216-1217. PubMed ID: 29097618
[TBL] [Abstract][Full Text] [Related]
37. Role of liquid biopsies in colorectal cancer.
Wills B; Gorse E; Lee V
Curr Probl Cancer; 2018 Nov; 42(6):593-600. PubMed ID: 30268335
[TBL] [Abstract][Full Text] [Related]
38. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
[TBL] [Abstract][Full Text] [Related]
39. Investigation of Efficacy Evaluation Comparison of cfDNA and CEA in Colorectal Cancer.
Yu D; An G; Xu L
Clin Lab; 2016 Oct; 62(10):1947-1953. PubMed ID: 28164530
[TBL] [Abstract][Full Text] [Related]
40. [Detection of KRAS mutation in colorectal cancer patients' cfDNA with droplet digital PCR].
Luo Y; Li Y
Sheng Wu Gong Cheng Xue Bao; 2018 Mar; 34(3):407-420. PubMed ID: 29577691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
